[Dyspepsia, Ulcer Disease – Helicobacter pylori, Gastroesophageal Reflux Disease].
Prevalence of H. pylori (HP) is declining, whereas reflux disease and the proportion of non-steroidal antiinflammatory drugs (NSAR) to HP-induced ulcers increase. Eradication heals HP-ulcer disease, interrupts cancerous progression and can improve dyspeptic symptoms. NSAR-ulcers heal under proton pump inhibitor (PPI) therapy but tend to recur after reexposition. Anticoagulants and antiplatlet agents increase the risk additionally. PPI reduces NSAR-ulcer recurrence. Reflux patients with severe inflammation and complications often need long-term therapy. Barrett’s esophagus patients are at risk of esophageal adenocarcinoma.
1 GastroZentrumKreuzlingen, Kreuzlingen.
Hans-Peter
HP
Wirth
D004415:Dyspepsia / Q000175:diagnosis / Q000209:etiology / Q000628:therapy*; D005764:Gastroesophageal Reflux / Q000175:diagnosis / Q000209:etiology / Q000628:therapy*; D016481:Helicobacter Infections / Q000175:diagnosis / Q000209:etiology / Q000628:therapy*; D016480:Helicobacter pylori; D006801:Humans; D010437:Peptic Ulcer / Q000175:diagnosis / Q000209:etiology / Q000628:therapy*; D012307:Risk Factors
Gastroduodenale Ulzera; Helicobacter pylori; Hélicobacter pylori; Refluxerkrankung; Ulkuskrankheit; anti-inflammatoires non-stéroïdiens; dyspepsia; gastroesophagealreflux disease; helicobacter pylori; inhibiteurs de la pompe à protons; maladie du reflux gastro-oesophagien; maladie ulcéreuse; ulcer disease; ulcère gastrointestinal